If You Invested in Exagen Inc. (XGN)

Exagen Inc. (Nasdaq: XGN) is a commercial-stage diagnostics company focused on autoimmune disease testing. According to the company, it is a leading provider of autoimmune diagnostics and autoimmune testing solutions, with a mission to provide clarity in autoimmune disease decision making and improve clinical outcomes for patients with chronic and debilitating autoimmune conditions. Exagen is based in San Diego County, California and operates a specialized laboratory that concentrates on rheumatic diseases.

Exagen’s business centers on its AVISE-branded testing portfolio. The company describes its flagship product, AVISE® CTD, as a test that enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s disease or Sjögren’s syndrome earlier and with greater accuracy. The AVISE CTD panel has also been enhanced with seronegative rheumatoid arthritis markers, including anti-PAD4, and incorporates biomarkers such as anti-RA33, anti-PAD4, and traditional biomarkers to improve diagnostic performance for rheumatoid arthritis, as highlighted in Exagen’s research presentations.

Exagen states that its laboratory is CLIA-certified and CAP-accredited and specializes in the testing of rheumatic diseases. The company reports that it delivers precise and timely results, supported by a suite or full suite of AVISE-branded tests designed for disease diagnosis, prognosis, and monitoring. In multiple company communications, Exagen emphasizes a focus on research, innovation, education, and patient-centered care as it addresses ongoing challenges in autoimmune disease management.

Business focus and testing portfolio

Exagen describes itself as a commercial-stage diagnostics company addressing the unmet need for accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. Earlier descriptions note that it markets testing products under its AVISE brand to provide accurate, timely, and differential diagnosis and to optimize treatment of autoimmune rheumatic diseases, and that it markets and sells solutions to community rheumatologists. More recent company materials consistently characterize Exagen as a leading provider of autoimmune diagnostics and autoimmune testing, with an emphasis on chronic autoimmune conditions.

The company’s AVISE CTD test is presented as its flagship offering. Exagen’s news and conference materials highlight AVISE CTD’s role in improving diagnostic accuracy for systemic lupus erythematosus (SLE), lupus nephritis, rheumatoid arthritis (including seronegative RA), and Sjögren’s disease or Sjögren’s syndrome. The company also references a broader AVISE-branded portfolio used for diagnosis, prognosis, and monitoring of rheumatic and autoimmune conditions.

Scientific and clinical orientation

Exagen repeatedly underscores its scientific orientation. Company news reports describe the acceptance of multiple abstracts at the American College of Rheumatology’s annual meeting, including a plenary presentation on a urinary biomarker panel for lupus nephritis and several poster presentations on kidney-specific biomarker panels, T cell biomarkers, and multianalyte lupus risk scores incorporating cell-bound complement activation products. These research activities are presented as part of Exagen’s efforts to enhance precision management of lupus nephritis, improve rheumatoid arthritis diagnostic accuracy, and differentiate systemic lupus erythematosus from other conditions.

The company also notes the commercial launch of seronegative RA markers for anti-PAD4 as an enhancement to the AVISE CTD panel and references continued development of a lupus nephritis platform. Leadership appointments, such as the Chief Scientific Officer role, are described in the context of strengthening autoimmune diagnostic research and precision diagnostics for autoimmune diseases.

Operations, laboratory, and market

Exagen reports that its laboratory is CLIA-certified and CAP-accredited and that it specializes in rheumatic disease testing. Across multiple disclosures, the company characterizes its testing as delivering precise and timely results. Earlier descriptions state that Exagen markets and sells its AVISE solutions to community rheumatologists, indicating a focus on clinicians who manage autoimmune rheumatic diseases.

The company’s communications describe it as a commercial-stage diagnostics company and a leading provider of autoimmune diagnostics and autoimmune testing solutions. Exagen’s stated mission is to transform care for patients with chronic and debilitating autoimmune conditions by providing clarity in clinical decision making through its testing portfolio.

Public company and regulatory context

Exagen Inc. is incorporated in Delaware and its common stock trades on the Nasdaq under the symbol XGN, as reported in company press releases and SEC filings. The company files periodic reports and current reports, including Forms 8-K that furnish press releases on financial results. These filings and disclosures provide information on Exagen’s operations, financial condition, and ongoing activities as a commercial-stage diagnostics company in the autoimmune space.

Role in autoimmune disease management

In its public statements, Exagen positions its AVISE CTD test and related AVISE-branded tests as tools that help clinicians diagnose complex autoimmune conditions earlier and with greater accuracy, and to monitor disease course. The company emphasizes the importance of addressing unmet needs in autoimmune rheumatic diseases, particularly conditions such as lupus, lupus nephritis, rheumatoid arthritis, and Sjögren’s disease or Sjögren’s syndrome. Through its focus on research, education, and patient-centered care, Exagen presents its testing portfolio as supporting improved decision making and outcomes in autoimmune disease management.